Global IV Bags Market - 2022-2029

Global IV Bags Market - 2022-2029

Market Overview

IV Bags Market size was valued at US$ xx million in 2021 and is estimated to reach US$ XX million by 2029, growing at a CAGR of 5% during the forecast period (2022-2029).

The IV bags are used to deliver different clinical nutritional fluids such as sodium chloride or other parenteral nutrition to the patient's body to treat a specific disease such as chronic diseases. The patient's IV fluids for specific purposes include medication administration, fluid, and electrolyte replacement and balance maintenance, blood or blood product delivery, and nutrient and nutritional supplement delivery.

Market Dynamics

The IV bags market growth is driven by the rise in prevalence of different diseases such as cancer, and neurological disorders rising adoption of IV therapy to take proper treatment of diseases, the increase in the geriatric population, and research and development activities.

The rising adoption of parenteral nutrition therapy is expected to drive the market growth

The rising prevalence of different diseases such as cancer and cardiovascular diseases is expected to boost the market over the forecast period. According to the WHO 2022 data report, due to non-communicable diseases 41 million people are killed each year. The disease includes cancers, diabetes, and others. In this case, parenteral nutrition is needed in an emergency case. The rising incidence of diseases such as malignancy, ischemic gut malady, gastrointestinal disorders, Crohn’s disease, and diabetic intricacies is propelled interest in parenteral nutrition. Increasing demand for parenteral nutrition therapy drives the IV bags market worldwide.

In addition, the key players are applying their market strategies such as new product launching and collaboration with other market players. For instance, In January 2022, ICU Medical acquire Smiths Medical from Smiths Group plc, this acquisition of Smiths Medical syringe and ambulatory infusion devices, vascular access, and vital care products to the ICU Medical portfolio strengthen a leading infusion therapy company with a more strong worldwide reach. Also, in March 2021, Fagron Sterile Services (FSS) expanded its product portfolio by introducing a new platform with multiple presentations available for Intravenous (IV) Bags.

The leaching chemical from IV Bags will hamper the growth of the market

However, PVC bags are not suitable for everyone’s formulations such as blood products. Mainly, Polyvinyl chloride (PVC) material is used for IV bags. PVC is not inherently flexible, plasticizers are added to achieve desirable properties. These plasticizers are not covalently bound to the PVC matrix and thus can easily leach into the surrounding solutions. The Leaching and extraction of di (2-ethylhexyl) phthalate (DEHP) from PVC bags have been reported often, with most DEHP found in bags utilized where blood is stored and delivered, or lipophilic drugs enteral and parenteral nutrition admixtures. This will hamper the market growth.

COVID-19 Impact Analysis

The appearance of COVID-19 considerably impacted the global IV bag market. In the pandemic, developed countries such as the United States have witnessed IV fluid and IV bag shortages, forcing healthcare facilities and providers to delay patient treatment or adopt other alternatives, resulting in a decrease in patient care. Public health authorities such as the FDA routinely request manufacturers to increase their ability to grow production capacity to address these shortages. In a pandemic, the United States is witness to a rapid rise in demand for convalescent plasma as COVID-19 cases increase in the states. The demand for IV fluid will increase with the increasing number of COVID-19 patients. On the other hand, the key players expanded their manufacturing production capabilities to meet the demand in the market. For instance, in April 2020, Baxter and Fresenius declared that they would deliver extra kidney dialysis equipment and other supplies to hospitals that require them for treating COVID-19 patients. In this, they provided a 75% increase in the production of premixed dialysate fluids with bagged lactate dialysate solution. Baxter also stated that it has increased the production of many other supplies, such as the mini-bag plus drug delivery system. The IV bags had positive market growth in the pandemic.

Segment Analysis

The multi-chamber IV bags segment is expected to grow at the fastest CAGR during the forecast period (2022-2029)

The multi-chamber IV bag segment is expected to boost the market over the period of the forecast. Multi-chamber IV bags provide numerous benefits, including improved patient safety because they reduce handling and the risk of contamination. Patients can receive standard mixtures of fluids such as lipids, amino acids, or glucose. They have separate seals and can store more than one nutritional fluid. In April 2022, the article published in the Chinese Society for Parenteral and Enternal Nutrition, mentioned the advantages of Multi-chmaber IV bags for home and hospital use.

The multi-chamber bag preparation has a variety of specifications and has the characteristics of ready-to-use, strict quality standards, reasonable prescription, and other characteristics, which can decrease configuration and prescription errors, lower bloodstream infections, and meet the clinical nutritional needs of the patients. The key players offer the only multi-chamber IV bag product portfolio in the market. For instance, B. Braun offers multi-chamber IV bags such as 3-chamber IV bags for emulsion infusion for nutrition purposes and also offers dual chamber IV bags for the purpose of separate filling and storage of lipid emulsion until the mixing of the full solution just before administration to the patient. These bags are available in different sizes such as 50 ml, 100 ml, 500 ml, 1000 ml, and others.

Geographical Analysis

North America region holds the largest market share of the global IV bags market

North America dominates the market for IV bags and is expected to show a similar trend over the forecast period. It is estimated to hold a significant market size over the forecast period (2022–2029) owing to a rising elderly population with diseases such as cancer and respiratory diseases, an advanced healthcare system, and the presence of market players. Patients who are undergoing an operative process receive IVs that provide essential fluids like saline. To store these fluids requires IV bags.

The larger patient pool means more demand for IV bags in the region. In addition, the presence of competitors, acquisitions, and new product launches boosts the market growth in the North American region. For instance, in February 2022, B. Braun Medical Company received United States FDA approval to start operations at its new IV saline solution manufacturing facility in Florida, United States. It will address the shortage of IV fluids and is expected to manufacture 0.9% sodium chloride for injection.

Also in March 2021, Fagron Sterile Services US (FSS) expanded its product portfolio with a new platform – intravenous (IV) bags in the United States.

Competitive Landscape

The IV bags market is a moderately competitive presence of local as well as global companies. Some of the key players which are contributing to the growth of the market are Baxter, B. Braun Melsungen AG, Pfizer, Inc., Fresenius Kabi AG, JW Life Science, RENOLIT, PolyCine GmbH, Sealed Air, ANGIPLAST PVT. LTD, Shanghai Solve Care Co Ltd., Kraton Corporation, and Jiangxi Sanxin Medtec Co., Ltd. among others. The major players are adopting several growth strategies such as product launches, acquisitions, and collaborations, which are contributing to the growth of the IV bags market globally.

For instance,

• In June 2022, Gufic Biosciences partnered with its French counterpart to manufacture new technology indigenously in India. The dual-chamber bags introduced by Gufic Biosciences were 2-Chamber IV Bags, made up of polypropylene (DEHP free) with a peelable aluminum foil allowing the storage of unstable drugs which require a reconstitution just before the administration to the patient.

Baxter Healthcare

Overview:

Baxter Healthcare is an American multinational healthcare company founded in 1940, headquartered in United States. It is provides the wide range of parenteral nutrition portfolio including vitamins and lipids, premix IV solutions, and pharmacy workflow management, labeling and compounding technology.

Treatment type Portfolio:

Baxter Sodium Chloride 0.9% IV Bags: It is available in variety of configurations and sizes such as 50mL, 100mL, 250mL, 500mL, and 1000mL Viaflex containers. These products are used for for intravenous administration. It is available in sodium chloride (0.9%), dextrose (5%) in water (D5W), and lactated ringers (LR).

The global IV bags market report would provide access to approximately 80+ market data tables, 70+ figures, and in the range of 250+ (approximate) pages.